UroGen Pharma Management
Management criteria checks 4/4
UroGen Pharma's CEO is Liz Barrett, appointed in Jan 2019, has a tenure of 5.25 years. total yearly compensation is $1.87M, comprised of 40.9% salary and 59.1% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $4.49M. The average tenure of the management team and the board of directors is 3.9 years and 5.9 years respectively.
Key information
Liz Barrett
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 40.9% |
| CEO tenure | 5.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09
UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?
Jun 14What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates
May 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$105m |
| Jun 30 2023 | n/a | n/a | -US$109m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$2m | US$764k | -US$110m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | -US$113m |
| Dec 31 2021 | US$4m | US$739k | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$117m |
| Dec 31 2020 | US$2m | US$637k | -US$128m |
| Sep 30 2020 | n/a | n/a | -US$137m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$121m |
| Dec 31 2019 | US$26m | US$695k | -US$105m |
Compensation vs Market: Liz's total compensation ($USD1.87M) is about average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Liz's compensation has been consistent with company performance over the past year.
CEO
Liz Barrett (61 yo)
5.3yrs
Tenure
US$1,870,560
Compensation
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$1.87m | 0.96% $ 4.5m | |
| Chief Financial Officer | 2.1yrs | US$738.02k | 0.10% $ 484.0k | |
| General Counsel | 3.7yrs | US$926.12k | 0.069% $ 321.5k | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive Vice President of Talent | less than a year | no data | no data | |
| Marketing Director | no data | no data | no data | |
| Executive Vice President of Research & Development and Technical Operations | 4.1yrs | no data | no data | |
| Chief Medical Officer | 6.3yrs | US$1.02m | 0.41% $ 1.9m | |
| Chief Commercial Officer | 4.1yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs & Quality | 4.1yrs | no data | no data | |
| Chief Business Officer | 3.6yrs | no data | no data | |
| Senior Vice President of Medical Affairs & Clinical Development | less than a year | no data | no data |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Management: URGN's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$1.87m | 0.96% $ 4.5m | |
| Independent Director | 6.9yrs | US$118.50k | 0.044% $ 206.0k | |
| Independent Director | 6.5yrs | US$123.50k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$121.00k | 0% $ 0 | |
| Independent Chairman | 11.3yrs | US$258.50k | 1.2% $ 5.6m | |
| Independent Director | 1.4yrs | US$242.83k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 1.7yrs | US$174.98k | 0% $ 0 |
5.9yrs
Average Tenure
66yo
Average Age
Experienced Board: URGN's board of directors are considered experienced (5.9 years average tenure).